Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Limosilactobacillus reuteri is a probiotic lactic acid bacterium found naturally in the gut and other body sites of humans and animals. It is notable for producing antimicrobial substances, especially reuterin, which inhibits the growth of pathogens without harming beneficial microbiota. L. reuteri strains exhibit anti-inflammatory and immunomodulatory effects, enhance gut barrier function, and can biosynthesize nutrients like folate and vitamin B12. It has been studied for roles in managing gastrointestinal infections, inflammatory and metabolic diseases, and as a general probiotic to support host health[1][3][4]. The term "Limosilactobacillus reuteri enhancement" refers to increasing the presence or activity of this probiotic, not to a molecular drug target.
Secretions of antimicrobial agents (e.g., reuterin inhibits growth of various pathogens by targets such as ribonucleotide reductase in microbes). Modulation of immune response (increase in anti-inflammatory cytokines, decrease in pro-inflammatory cytokines such as TNF-α). Competition with pathogens for gut colonization or adherence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Limosilactobacillus reuteri (L. reuteri).